Oleptro

Insomnia, Schizophrenia, Alzheimer's Disease + 8 more

Treatment

1 FDA approval

20 Active Studies for Oleptro

What is Oleptro

Trazodone

The Generic name of this drug

Treatment Summary

Trazodone is an antidepressant medication that is used to treat depression in adults. It is similar in efficacy to other antidepressants like tricyclic antidepressants, selective serotonin reuptake inhibitors, and serotonin-norepinephrine reuptake inhibitors. Unlike other antidepressant drugs, Trazodone does not cause anxiety, sexual symptoms, or insomnia. Trazodone works on different receptors than other antidepressants, and was approved by the FDA in 1981.

Trazodone Hydrochloride

is the brand name

Oleptro Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Trazodone Hydrochloride

Trazodone

1987

344

Approved as Treatment by the FDA

Trazodone, otherwise called Trazodone Hydrochloride, is approved by the FDA for 1 uses which include Depression .

Depression

Effectiveness

How Oleptro Affects Patients

Trazodone is used to treat depression and can help with insomnia due to its sedative effects. Taking it may make you feel drowsy or forgetful, especially if you are elderly. However, it can also be dangerous as it can cause priapism, which is a long-lasting and painful erection that can cause permanent damage to the nerves if not treated. If you experience this, you should seek medical attention right away.

How Oleptro works in the body

The exact way that trazodone works is not known, but it is thought to block the reuptake of serotonin in the brain. This prevents serotonin from being broken down and allows it to stay in the brain longer, which can help reduce symptoms of depression. Trazodone also blocks histamine and alpha-1-adrenergic receptors, which helps prevent further serotonin breakdown. Lastly, trazodone inhibits serotonin transporters, which helps keep serotonin in the brain longer. All of these processes help reduce symptoms of depression.

When to interrupt dosage

The suggested measure of Oleptro is contingent upon the diagnosed condition, for example, Insomnia, Schizophrenia and Pain. The measure of dosage also differs as per the technique of delivery (e.g. Tablet, extended release - Oral or Tablet - Oral) outlined in the given table.

Condition

Dosage

Administration

Insomnia

, 50.0 mg, 100.0 mg, 150.0 mg, 300.0 mg, 68.25 mg, 75.0 mg, 0.5 mg, 1.0 mg

, Oral, Tablet, Tablet - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, extended release, Tablet, extended release - Oral, Kit

Schizophrenia

, 50.0 mg, 100.0 mg, 150.0 mg, 300.0 mg, 68.25 mg, 75.0 mg, 0.5 mg, 1.0 mg

, Oral, Tablet, Tablet - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, extended release, Tablet, extended release - Oral, Kit

Generalized Anxiety Disorder

, 50.0 mg, 100.0 mg, 150.0 mg, 300.0 mg, 68.25 mg, 75.0 mg, 0.5 mg, 1.0 mg

, Oral, Tablet, Tablet - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, extended release, Tablet, extended release - Oral, Kit

Pain

, 50.0 mg, 100.0 mg, 150.0 mg, 300.0 mg, 68.25 mg, 75.0 mg, 0.5 mg, 1.0 mg

, Oral, Tablet, Tablet - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, extended release, Tablet, extended release - Oral, Kit

Alzheimer's Disease

, 50.0 mg, 100.0 mg, 150.0 mg, 300.0 mg, 68.25 mg, 75.0 mg, 0.5 mg, 1.0 mg

, Oral, Tablet, Tablet - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, extended release, Tablet, extended release - Oral, Kit

Eating Disorders

, 50.0 mg, 100.0 mg, 150.0 mg, 300.0 mg, 68.25 mg, 75.0 mg, 0.5 mg, 1.0 mg

, Oral, Tablet, Tablet - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, extended release, Tablet, extended release - Oral, Kit

Depression

, 50.0 mg, 100.0 mg, 150.0 mg, 300.0 mg, 68.25 mg, 75.0 mg, 0.5 mg, 1.0 mg

, Oral, Tablet, Tablet - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, extended release, Tablet, extended release - Oral, Kit

Pain

, 50.0 mg, 100.0 mg, 150.0 mg, 300.0 mg, 68.25 mg, 75.0 mg, 0.5 mg, 1.0 mg

, Oral, Tablet, Tablet - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, extended release, Tablet, extended release - Oral, Kit

Alzheimer's Disease

, 50.0 mg, 100.0 mg, 150.0 mg, 300.0 mg, 68.25 mg, 75.0 mg, 0.5 mg, 1.0 mg

, Oral, Tablet, Tablet - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, extended release, Tablet, extended release - Oral, Kit

Fibromyalgia

, 50.0 mg, 100.0 mg, 150.0 mg, 300.0 mg, 68.25 mg, 75.0 mg, 0.5 mg, 1.0 mg

, Oral, Tablet, Tablet - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, extended release, Tablet, extended release - Oral, Kit

Alcoholism

, 50.0 mg, 100.0 mg, 150.0 mg, 300.0 mg, 68.25 mg, 75.0 mg, 0.5 mg, 1.0 mg

, Oral, Tablet, Tablet - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, extended release, Tablet, extended release - Oral, Kit

Warnings

Oleptro Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

There are 20 known major drug interactions with Oleptro.

Common Oleptro Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The serum concentration of Abemaciclib can be decreased when it is combined with Trazodone.

Abexinostat

Major

The risk or severity of QTc prolongation can be increased when Trazodone is combined with Abexinostat.

Acebutolol

Major

The risk or severity of QTc prolongation can be increased when Trazodone is combined with Acebutolol.

Acepromazine

Major

Trazodone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.

Aceprometazine

Major

The risk or severity of QTc prolongation can be increased when Trazodone is combined with Aceprometazine.

Oleptro Toxicity & Overdose Risk

The toxic dose of trazodone for rats is 690mg/kg. An overdose of trazodone can cause difficulty breathing, slow heartbeat, low blood pressure, confusion, lack of coordination, and even coma. It can also lead to a persistent and unrelievable erection of the penis that may be permanent if not treated quickly. There is no specific antidote for a trazodone overdose. If an overdose occurs, it is possible that trazodone was mixed with other drugs, so contact a poison control center for guidance. Dialysis will not help remove trazodone from the body.

image of a doctor in a lab doing drug, clinical research

Oleptro Novel Uses: Which Conditions Have a Clinical Trial Featuring Oleptro?

A formidable number of 948 active trials are presently analyzing the potential of Oleptro to ameliorate Schizophrenia, Alzheimer's Disease and Pain.

Condition

Clinical Trials

Trial Phases

Schizophrenia

97 Actively Recruiting

Phase 3, Not Applicable, Early Phase 1, Phase 4, Phase 1, Phase 2

Generalized Anxiety Disorder

183 Actively Recruiting

Not Applicable, Phase 2, Early Phase 1, Phase 4, Phase 1, Phase 3

Depression

213 Actively Recruiting

Phase 3, Phase 2, Not Applicable, Phase 4, Phase 1, Early Phase 1

Alzheimer's Disease

112 Actively Recruiting

Phase 2, Phase 3, Not Applicable, Phase 1, Phase 4, Early Phase 1

Pain

0 Actively Recruiting

Alzheimer's Disease

39 Actively Recruiting

Phase 4, Phase 2, Phase 3, Not Applicable, Phase 1

Pain

0 Actively Recruiting

Insomnia

0 Actively Recruiting

Alcoholism

7 Actively Recruiting

Not Applicable, Phase 2, Phase 3

Eating Disorders

1 Actively Recruiting

Not Applicable

Fibromyalgia

0 Actively Recruiting

Oleptro Reviews: What are patients saying about Oleptro?

5

Patient Review

12/7/2010

Oleptro for Major Depressive Disorder

I strongly recommend avoiding this treatment. I had terrible dreams and felt like I had a hangover the next day.

5

Patient Review

2/5/2012

Oleptro for Major Depressive Disorder

It was tough to fall asleep after taking this medication, and I also experienced some discomfort with my muscles. However, I didn't gain any weight, which is great.

5

Patient Review

2/7/2011

Oleptro for Major Depressive Disorder

I experienced vertigo, loss of focus and concentration, slurred speech (like being drunk), and extreme difficulty waking up in the morning. I was also very tired.

5

Patient Review

10/7/2010

Oleptro for Major Depressive Disorder

4.7

Patient Review

10/13/2011

Oleptro for Major Depressive Disorder

I've been taking Oleptro for four months now and it's done wonders for my mood, restless legs, sleep quality, and even some of my ADHD symptoms. The only downside is that insurance doesn't cover it so I have to rely on samples from my doctor.

4.7

Patient Review

5/6/2011

Oleptro for Major Depressive Disorder

I had to stop taking Lexapro because I started putting on weight. However, Oleptro has worked great for me so far. Not only was I able to fall asleep, but I stayed asleep through the night--a problem Lunesta couldn't address. My doctor is now treating my depression and sleep problems with a single 300mg dose of Oleptro taken at bedtime.

4.7

Patient Review

3/9/2011

Oleptro for Major Depressive Disorder

I unfortunately had to discontinue this medication because it caused me intense night sweats and muscle aches. However, while I was taking it I did notice a significant improvement in my depression.

2.7

Patient Review

2/8/2011

Oleptro for Major Depressive Disorder

So far, I'm really liking this. I've tried Lexapro and Pristiq in the past, but both came with a range of unpleasant side effects. This medication has helped me sleep better than ever before, and I haven't experienced any weight gain or sexual side effects.

2.3

Patient Review

10/29/2010

Oleptro for Major Depressive Disorder

I don't have any trouble sleeping at night or gaining weight while taking this medication, which is great.

2

Patient Review

2/27/2011

Oleptro for Major Depressive Disorder

I experienced some really unpleasant side effects while taking this medication, including dizziness, sexual dysfunction, and tingling/numbness in my extremities. It also didn't help me sleep any better as was intended, so I stopped taking it.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about oleptro

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Oleptro still available?

"The Oleptro brand name has been discontinued and there are no generic equivalents available in the U.S. as of May 23, 2022."

Answered by AI

Is trazodone a sleeping pill?

"The medication trazodone was originally designed to treat depression and anxiety disorders, but is now also commonly prescribed as a sleep aid for those who suffer from acute insomnia."

Answered by AI

What is Oleptro used for?

"Oleptro is an antidepressant medication used to treat major depressive disorder. It specifically works to balance chemicals in the brain that may be unbalanced in people who suffer from depression. In addition to treating major depressive disorder, Oleptro may also be used for other purposes not listed in the medication guide."

Answered by AI

Is Oleptro the same as trazodone?

"Trazodone hydrochloride extended-release tablets are a prescription medicine used to treat the symptoms of depression."

Answered by AI

Clinical Trials for Oleptro

Have you considered Oleptro clinical trials?

We made a collection of clinical trials featuring Oleptro, we think they might fit your search criteria.
Go to Trials
Image of University of South Florida in Tampa, United States.

WeACT Program for Caregivers of People With Dementia

18+
All Sexes
Tampa, FL

The goal of this clinical trial is to learn whether WeACT, a self-paced, web-based program, is feasible and helpful for adult family caregivers of a relative living with dementia. WeACT is based on acceptance and commitment therapy (ACT), which teaches skills to handle difficult thoughts and feelings and take steps toward what matters most. The main questions this study aims to answer are: * Can caregivers complete WeACT as planned? * Do caregivers show improvements in mental health and coping after using WeACT? * What are caregivers' experiences with the program, and what suggestions do they have to improve it? Participants will: * Complete six self-paced weekly online modules and use the daily practice section during the program. * Complete online questionnaires before starting and after completing the program. * Take part in one online interview about their experience.

Waitlist Available
Has No Placebo

University of South Florida

Areum Han

Image of Fred Hutch/University of Washington Cancer Consortium in Seattle, United States.

Psilocybin Therapy for Anxiety and Depression in Cancer

18 - 85
All Sexes
Seattle, WA

This phase II trial tests the safety, side effects and how well group retreat psilocybin therapy works for the treatment of anxiety and depression in patients with solid tumors that have spread from where they first started (primary site) to other places in the body (metastatic) or with hematologic cancers for which no treatment is currently available (incurable). For patients with metastatic, incurable cancer, unrelieved anxiety and existential distress can cause profound suffering. Psilocybin therapy can relieve anxiety and existential distress by disrupting patterns of thinking that contribute to anxiety and depression. Psilocybin is a substance being studied in the treatment of anxiety or depression in patients with cancer. In this study, a pharmaceutical grade of psilocybin will be used that has been approved by the FDA for research, provided by Filament Health. Psilocybin acts on the brain by resetting the brain's activity and increasing connections between brain regions, particularly those involved in mood regulation and self-perception. In this study psilocybin is combined with structured discussions and reflections that enable patients to have new insights about their situation. In a prior study, group retreat psilocybin therapy was proven to be safe and this study tests a refined dosing regimen for symptoms of anxiety and depression in patients with metastatic solid tumors or incurable hematologic malignancies.

Phase 2
Waitlist Available

Fred Hutch/University of Washington Cancer Consortium

Anthony Back, MD

Image of Wahwala Iyohlogya/Peaceful Means in Pine Ridge, United States.

Lakota Family Acceptance Program for Depression and Anxiety

Any Age
All Sexes
Pine Ridge, SD

The goal of this open pilot trial (OPT) is to develop a Lakota-adapted Family Acceptance Project (LFAP) for Indigenous 2SLGBTQ+ youth and their caregivers. The OPT is specifically focused on acceptability, feasibility, and safety of programming and research protocols. The investigators will also examine pre- to post- changes on outcomes for the sole purposes of making sure scores on measures are changing in the hypothesized direction (e.g., depression scores are going from moderate to minimal as opposed to no change or depression scores increasing). Once enrolled in the study, participants complete a baseline survey. Then participants will engage in LFAP which is an 8-session group intervention; sessions will be scheduled once a week for eight weeks (at 2 hours per session). Participants will complete survey instruments before and immediately after the program sessions, in addition to post-program surveys and an exit interview.

Recruiting
Has No Placebo

Wahwala Iyohlogya/Peaceful Means (+1 Sites)

Katie Edwards, PhD

Image of Johns Hopkins Bayview Medical Center in Baltimore, United States.

VR-Enhanced PMR for Post-Burn Symptoms

18+
All Sexes
Baltimore, MD

The goal of this clinical trial is to learn whether progressive muscle relaxation (PMR), delivered either alone or enhanced with virtual reality (VR), can help treat chronic symptom, such as pain, itch, anxiety, sleep disturbances, and fatigue, in adult burn survivors. The main questions it aims to answer are: * Does VR-enhanced PMR (VR-PMR) reduce chronic pain, anxiety, itch, sleep disturbances, and fatigue more effectively than standard PMR? * Is VR-PMR a feasible and acceptable self-administered home-based intervention for burn survivors? Researchers will compare two self-administered intervention conditions, VR-enhanced PMR and standard PMR, using a randomized to sequence crossover design to see if VR technology enhances the therapeutic effects of PMR on chronic symptom management in burn survivors. Participants will: * Complete home-based sessions of VR-enhanced PMR * Complete home-based sessions of standard PMR * Report symptoms such as pain, itch, anxiety, sleep disturbances, and fatigue throughout the study * Use VR equipment provided for the intervention period (during the VR-PMR arm)

Recruiting
Has No Placebo

Johns Hopkins Bayview Medical Center

Sheera Lerman Zohar, PhD

Have you considered Oleptro clinical trials?

We made a collection of clinical trials featuring Oleptro, we think they might fit your search criteria.
Go to Trials
Image of University of Texas Medical Branch, Galveston in Galveston, United States.

Smartphone App for Cognitive Impairment

50 - 100
All Sexes
Galveston, TX

The objective of this project is to test the feasibility of using a smartphone app in a community setting through collaborating with community-based organizations. The app is called utmbHealthyBrain and it has three activities: (1) drawing, (2) Tai-Chi and meditation, and (3) prayer reading. It also has a "share" function to enable users to interact with their family and friend. These activities can be translated to humans' well-beings such as a more stable emotion, more muscle movement, and better social engagement. This app does not collect any personal data and users are not required to register an account either. The overall study period is 6 weeks including one introduction session (week 1), four weeks of intervention (week 2 to 5), and final feedback session (week 6).

Waitlist Available
Has No Placebo

University of Texas Medical Branch, Galveston

Wei-Chen Lee, PhD

Have you considered Oleptro clinical trials?

We made a collection of clinical trials featuring Oleptro, we think they might fit your search criteria.
Go to Trials